The advent of high-throughput sequencing technology has led to the discovery of abnormal genomic variants in cancer patients as novel therapeutic targets, such as the EML4-ALK fusion gene in non-small-cell lung cancer (NSCLC) [3]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.